Phenotyping Tumor Heterogeneity through Proteogenomics: Study Models and Challenges
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25168830 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Diletta Piana und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Biotechnological Sciences, Intensivological and Perioperative Clinics, Università Cattolica del Sacro Cuore, 00168 Rome, Italy. Hauptthemen laut MEDLINE: Proteogenomics, Neoplasms, Phenotype. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 189 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Tumor heterogeneity refers to the diversity observed among tumor cells: both between different tumors (inter-tumor heterogeneity) and within a single tumor (intra-tumor heterogeneity). These cells can display distinct morphological and phenotypic characteristics, including variations in cellular morphology, metastatic potential and variability treatment responses among patients. Therefore, a comprehensive understanding of such heterogeneity is necessary for deciphering tumor-specific mechanisms that may be diagnostically and therapeutically valuable. Innovative and multidisciplinary approaches are needed to understand this complex feature. In this context, proteogenomics has been emerging as a significant resource for integrating omics fields such as genomics and proteomics. By combining data obtained from both Next-Generation Sequencing (NGS) technologies and mass spectrometry (MS) analyses, proteogenomics aims to provide a comprehensive view of tumor heterogeneity. This approach reveals molecular alterations and phenotypic features related to tumor subtypes, potentially identifying therapeutic biomarkers. Many achievements have been made; however, despite continuous advances in proteogenomics-based methodologies, several challenges remain: in particular the limitations in sensitivity and specificity and the lack of optimal study models. This review highlights the impact of proteogenomics on characterizing tumor phenotypes, focusing on the critical challenges and current limitations of its use in different clinical and preclinical models for tumor phenotypic characterization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Basic Biotechnological Sciences, Intensivological and Perioperative Clinics, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
- Departmen Unity of Chemistry, Biochemistry and Clinical Molecular Biology, Department of Diagnostic and Laboratory Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
- Departmental Unit of Molecular and Genomic Diagnostics, Genomics Core Facility, Gemelli Science and Technology Park (G-STeP), Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
- Phase 1 Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
ORCID-Profile: Diletta Piana, Federica Iavarone, Gennaro Daniele, Angelo Minucci, Viviana Greco
Zitieren
APA
Piana, D., Iavarone, F., De Paolis, E., Daniele, G., Parisella, F., Minucci, A., Greco, V., & Urbani, A. (2024). Phenotyping Tumor Heterogeneity through Proteogenomics: Study Models and Challenges. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25168830
Vancouver
Piana D, Iavarone F, De Paolis E, Daniele G, Parisella F, Minucci A, et al. Phenotyping Tumor Heterogeneity through Proteogenomics: Study Models and Challenges. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25168830
BibTeX
@article{Piana2024,
author = {Piana, Diletta and Iavarone, Federica and De Paolis, Elisa and Daniele, Gennaro and Parisella, Federico and Minucci, Angelo and Greco, Viviana and Urbani, Andrea},
title = {Phenotyping Tumor Heterogeneity through Proteogenomics: Study Models and Challenges},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25168830}
}
EUVIMED